Nykode Therapeutics has been granted a patent for an anticancer vaccine comprising polynucleotides or polypeptides. The vaccine features a polynucleotide encoding a targeting unit, dimerization unit, and an antigenic unit with 3 to 50 cancer neoepitope sequences, aimed at cancer treatment. GlobalData’s report on Nykode Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Nykode Therapeutics, CAR-T cell based therapies was a key innovation area identified from patents. Nykode Therapeutics's grant share as of July 2024 was 22%. Grant share is based on the ratio of number of grants to total number of patents.
Anticancer vaccine comprising neoepitopes and polynucleotides
The granted patent US12059459B2 outlines a novel anticancer neoepitope composition designed to enhance cancer treatment. The composition includes a DNA polynucleotide that encodes a targeting unit, a dimerization unit, a first linker, and an antigenic unit. The antigenic unit is characterized by containing multiple cancer neoepitope sequences, with the number of sequences (n) ranging from 3 to 50. Each cancer neoepitope sequence is specified to have a length between 7 to 30 amino acids, and the composition allows for variations in the number of copies of these sequences. The arrangement of antigenic subunits is strategically designed to optimize immunogenicity, with more antigenic sequences positioned towards the beginning of the unit and hydrophobic sequences centrally located.
Additionally, the patent details specific structural features of the composition, such as the use of flexible linkers, including a Serine-Glycine linker, and the overall length of the antigenic unit, which can range from approximately 300 to 1000 amino acids. The targeting and dimerization units are defined by specific amino acid sequences, and the cancer neoepitopes are derived from tumors with high mutational loads, including melanoma, lung cancer, breast cancer, prostate cancer, and colon cancer. The patent also describes a method for treating cancer by administering this composition to patients, indicating its potential application in therapeutic settings.
To know more about GlobalData’s detailed insights on Nykode Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
